Glaukos (GKOS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual invest ...

Glaukos (GKOS) closed the last trading session at $95.64, gaining 3.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $128.54 indicates a 34.4% upside potential.The average comprises 13 short-term price targets ranging from a low of $72 to a high of $182, with a standard deviation of $33.39. While the lowest estimate indicates a decline of 24.7% from the current price level, the m ...

Summary of Glaukos (GKOS) 2025 Conference Call Company Overview - **Company**: Glaukos Corporation (GKOS) - **Industry**: Medical Supplies and Devices, specifically focused on glaucoma treatment Key Points and Arguments Interventional Glaucoma Paradigm Shift - The interventional glaucoma approach is gaining acceptance as a proactive method to manage glaucoma, moving away from traditional drop treatments which patients often neglect [3][4] - The company emphasizes the need for changing practice patterns and educating healthcare providers to adopt this new approach effectively [5][6] - The transition to an interventional approach is expected to take about ten years, with a focus on improving patient outcomes [6] Physician Adoption and Challenges - Physician receptiveness varies, but the main challenge lies in translating positive clinical feedback into actionable changes in practice [7][8] - The company is focused on addressing operational challenges within practices, such as educating referral networks and changing administrative processes [9] Market Dynamics and Treatment Modalities - The company acknowledges the competition from other treatment modalities like SLT and emphasizes the importance of interventional approaches in patient care [12][16] - The average patient remains in care for over 20 years, necessitating multiple interventions to manage their condition effectively [17] iDose Product Launch and Reimbursement - The iDose product has seen successful launch and is currently focused on securing reimbursement from various Medicare Administrative Contractors (MACs) [18][19] - The reimbursement landscape is segmented into three tiers, with varying levels of predictability and success in claims processing [19][20] - The company is actively working to streamline reimbursement processes and is optimistic about future growth in iDose contributions [26][27] Financial Performance and Cash Flow - The company aims to achieve cash flow breakeven in the near term, with expectations that iDose will contribute positively to gross margins over time [41][42] - Operating expenses are growing at a slower rate than revenue, indicating operational leverage is being achieved [45] Sales Strategy and Market Access - The sales force is deemed sufficient, with plans to fill geographic gaps as needed [47] - The company is focusing on supporting healthcare providers in navigating the complexities of commercial payer systems, which differ significantly from Medicare processes [36][37] Future Outlook and Growth Potential - The company anticipates continued growth in the MIGS market, with expectations of mid-single-digit growth rates in the long term [57][58] - The focus remains on increasing standalone utilization of iDose and other products, which may influence market dynamics and physician preferences [58] Additional Important Insights - The company is investing in educational initiatives and industry collaborations to promote best practices in interventional glaucoma [11] - The reimbursement process is described as a data collection effort by MACs to ensure medical necessity and appropriate payment calculations [23][24] - The company is also working on new product developments, including the Trio system, which aims to enhance in-office procedures [50][51] This summary encapsulates the key discussions and insights from the Glaukos conference call, highlighting the company's strategic focus on interventional glaucoma, product launches, and market dynamics.

Glaukos (GKOS) FY Conference June 03, 2025 01:40 PM ET Speaker0 How's it going, everyone? I'm gonna step in. My name is Macaulay Cobain. I work under Margaret Kayser covering med tech. We're gonna have Glaukos present for us. We have management with us today. You can go to WilliamBlair.com for a full list of our disclosures, and we'll, we'll have Alex kick it off here. Speaker1 Alright. Thank you all for coming and joining us, this afternoon and to talk a little bit about Glaukos. My pleasure to, speak to y ...

Summary of Glaukos (GKOS) 2025 Conference Call Company Overview - **Company**: Glaukos Corporation (GKOS) - **Event**: 2025 Conference Call held on May 27, 2025 Key Points on iDose Reimbursement and Performance - **Reimbursement Status**: Progress is being made with Medicare administrators, including Noridian, Novitas, and First Coast, with increasing payments for the drug and facility fees [2][3][10] - **Professional Fee Adjudication**: Ongoing efforts to streamline professional fee payments, with some Medicare Administrative Contractors (MACs) showing signs of improvement [3][5] - **Volume Generation**: The timing of reimbursement progress is tied to generating procedural volumes, which is critical for establishing a systematic reimbursement process [4][5] - **ASP Comparison**: iDose's Average Selling Price (ASP) is competitive, with the product containing seven times the amount of drug compared to Darista, which has comprehensive coverage across payers [7][9][10] - **Coverage Status**: Approximately 50% of lives are covered under commercial plans and Medicare Advantage, with ongoing efforts to expand access [10][11] - **Market Dynamics**: iDose is positioned as a second or third-line therapy initially, with plans to drive it closer to first-line therapy over time [12] Financial Performance and Projections - **Q1 2025 Performance**: The company reported exceptional progress in the market, with Noridian fully operational and increasing payments from Novitas and First Coast [14][19] - **Sales Guidance**: For 2025, the guidance for iDose sales is projected between $120 million to $125 million, with expectations for a stronger second half of the year due to seasonality and backlog building [23][24] - **Gradual Launch**: The launch of iDose is expected to be gradual and methodical, with a focus on education and operationalizing reimbursement processes [37][39] Long-term Outlook - **Peak Sales Estimates**: Peak sales expectations for iDose have not changed significantly but have increased on a risk-adjusted basis due to positive real-world performance [45] - **Market Potential**: The company is optimistic about the long-term market opportunity, with a focus on expanding access and operational efficiency in physician offices [42][44] U.S. Stent Business Insights - **Recent Performance**: The U.S. stent business experienced mid-single-digit growth in early 2024 but faced challenges due to Local Coverage Determinations (LCDs) impacting procedures [47][48] - **Guidance Adjustments**: Guidance for 2025 has been adjusted to reflect the impact of LCDs, with expectations for recovery as awareness and adaptation to these changes improve [52][54] Profitability Goals - **Cash Flow Breakeven**: The company aims to achieve free cash flow breakeven in the near term while continuing to make necessary investments [56] Additional Notes - **Investor Enthusiasm**: There is strong enthusiasm from investors regarding the product's clinical performance, but the launch pace is primarily influenced by reimbursement dynamics [31][35] - **Education and Support**: The company emphasizes the importance of educating physicians and their staff on the procedural aspects and reimbursement processes to ensure successful adoption [29][30]

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 34.9% so far this year compared with the industry’s 7.5% decline. The S&P 500 Index has increased 0.7% in the same time frame.Glaukos, with a market capitalization of $5.48 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-q ...

Core Insights - Glaukos reported $106.66 million in revenue for Q1 2025, a 24.6% year-over-year increase, with an EPS of -$0.22 compared to -$0.70 a year ago, exceeding the Zacks Consensus Estimate of $102.72 million by 3.84% [1] - The company achieved an EPS surprise of 33.33%, with the consensus EPS estimate being -$0.33 [1] Revenue Breakdown - U.S. revenues reached $75.07 million, surpassing the average estimate of $71.54 million, reflecting a 30.1% year-over-year increase [4] - International revenues totaled $31.59 million, slightly above the average estimate of $31.35 million, marking a 13.1% year-over-year increase [4] - Corneal Health revenues in the international market were $2.59 million, below the average estimate of $2.78 million, showing a decline of 4.1% year-over-year [4] - U.S. Corneal Health revenues were $15.94 million, exceeding the average estimate of $15.50 million, with a 1.5% year-over-year increase [4] - International Glaucoma revenues amounted to $29.01 million, surpassing the average estimate of $28.57 million, reflecting a 14.9% year-over-year increase [4] - U.S. Glaucoma revenues reached $59.13 million, exceeding the average estimate of $56.03 million, with a significant 40.8% year-over-year increase [4] - Total Corneal Health revenues were $18.53 million, slightly above the average estimate of $18.28 million, representing a 0.7% year-over-year increase [4] - Total Glaucoma revenues were $88.14 million, exceeding the average estimate of $84.60 million, reflecting a 31.1% year-over-year increase [4] Stock Performance - Glaukos shares have returned -5.8% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Glaukos Corporation (GKOS) reported first-quarter 2025 adjusted loss of 22 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 33 cents. The figure also improved from the year-ago quarter’s adjusted loss of 70 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The GAAP loss per share was 32 cents compared with the prior-year quarter’s reported loss of 82 cents.Revenue DetailsGlaukos registered revenues of $106.7 million in the first quart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 33-0945406 (I.R.S. Em ...

Glaukos (GKOS) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate AffairsThomas Burns - Chairman & CEOThomas Stephan - Vice PresidentJoseph Gilliam - President & COOAllen Gong - Vice PresidentJoanne Wuensch. - Managing DirectorRichard Newitter - Managing DirectorAlex Thurman - Senior VP & CFOAnthony Petrone - Managing DirectorPatrick Wood - Managing Director Conference Call Participants Ryan Zimmerman - Managing Director & Medical Technology AnalystLawre ...